Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)

NCT02231736 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2014-09-04

No results posted yet for this study

Summary

The purpose of the study is to determine whether glycemic control (HbA1c) is linked to chromosomal damage in type 2 Diabetes patients

Conditions

Sponsors & Collaborators

  • University of Vienna

    lead OTHER

Principal Investigators

  • Karl-Heinz Wagner, PhD · UNIVIE

Eligibility

Min Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-02-28

Countries

  • Austria

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02231736 on ClinicalTrials.gov